

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/776,933	02/10/2004	Bo Hansen	58614 (71432)	2102	
	7590 10/29/200 NGELL PALMER & I	EXAM	EXAMINER		
P.O. BOX 5587	74	SHIN, D	SHIN, DANA H		
BOSTON, MA 02205			ART UNIT	PAPER NUMBER	
		1635			
•			MAIL DATE	DELIVERY MODE	
		·	10/29/2007	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

## Advisory Action Before the Filing of an Appeal Brief

Application No.		Applicant(s)	-	
10/776,933		HANSEN ET AL.		
	Examiner	Art Unit		
	Dana Shin	1635		

	Dana Shin	1635			
The MAILING DATE of this communication appe	ars on the cover sheet with the d	orrespondence add	iress		
THE REPLY FILED 19 September 2007 FAILS TO PLACE THI					
1.  The reply was filed after a final rejection, but prior to or on this application, applicant must timely file one of the follow places the application in condition for allowance; (2) a No a Request for Continued Examination (RCE) in compliance time periods:	the same day as filing a Notice of ving replies: (1) an amendment, aff tice of Appeal (with appeal fee) in c	Appeal. To avoid aba idavit, or other evider compliance with 37 C	nce, which FR 41.31; or (3)		
a) $\square$ The period for reply expires $\underline{4}$ months from the mailing date	of the final rejection.				
b) The period for reply expires on: (1) the mailing date of this Advisory Action, or (2) the date set forth in the final rejection, whichever is later. no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of the final rejection.  Examiner Note: If box 1 is checked, check either box (a) or (b). ONLY CHECK BOX (b) WHEN THE FIRST REPLY WAS FILED WITHIN					
TWO MONTHS OF THE FINAL REJECTION. See MPEP 7	06.07(f).				
Extensions of time may be obtained under 37 CFR 1.136(a). The date have been filed is the date for purposes of determining the period of exunder 37 CFR 1.17(a) is calculated from: (1) the expiration date of the set forth in (b) above, if checked. Any reply received by the Office later may reduce any earned patent term adjustment. See 37 CFR 1.704(b)	tension and the corresponding amount shortened statutory period for reply orig than three months after the mailing da	of the fee. The appropr inally set in the final Offi	iate extension fee ice action; or (2) as		
NOTICE OF APPEAL  2. The Notice of Appeal was filed on A brief in comp filing the Notice of Appeal (37 CFR 41.37(a)), or any external a Notice of Appeal has been filed, any reply must be filed AMENDMENTS	nsion thereof (37 CFR 41.37(e)), to	avoid dismissal of th	ns of the date of ne appeal. Since		
3. X The proposed amendment(s) filed after a final rejection,	but prior to the date of filing a brief	will not be entered b	ecause		
(a) They raise new issues that would require further co	nsideration and/or search (see NO	TE below):	coaucc		
(b) They raise the issue of new matter (see NOTE belo	w);	•			
<ul><li>(c) They are not deemed to place the application in bet appeal; and/or</li></ul>	ter form for appeal by materially re	ducing or simplifying	the issues for		
(d) They present additional claims without canceling a	corresponding number of finally rej	ected claims.			
NOTE: See Continuation Sheet. (See 37 CFR 1.1			•		
1. The amendments are not in compliance with 37 CFR 1.13		mpliant Amendment	(PTOL-324).		
5. Applicant's reply has overcome the following rejection(s)	·		•		
<ol> <li>Newly proposed or amended claim(s) would be al non-allowable claim(s).</li> </ol>		•			
7. For purposes of appeal, the proposed amendment(s): a) how the new or amended claims would be rejected is provided the status of the claim(s) is (or will be) as follows:	☑ will not be entered, or b) ☐ will will will be will will will will will will will wil	ll be entered and an e	explanation of		
Claim(s) allowed: Claim(s) objected to:	·				
Claim(s) rejected: 2,4-9,14-16,47-50,53,54,91 and 93-97.					
Claim(s) withdrawn from consideration:	•				
AFFIDAVIT OR OTHER EVIDENCE			<i>:</i>		
3. The affidavit or other evidence filed after a final action, bu because applicant failed to provide a showing of good and was not earlier presented. See 37 CFR 1.116(e).	d sufficient reasons why the affidav	it or other evidence is	s necessary and		
7. The affidavit or other evidence filed after the date of filing entered because the affidavit or other evidence failed to o showing a good and sufficient reasons why it is necessary.	vercome <u>all</u> rejections under appear y and was not earlier presented. S	al and/or appellant fai ee 37 CFR 41.33(d)(	ils to provide a 1).		
IO. ☐ The affidavit or other evidence is entered. An explanation REQUEST FOR RECONSIDERATION/OTHER	n of the status of the claims after e	ntry is below or attach	ied.		
11.  The request for reconsideration has been considered bu See Continuation Sheet.	t does NOT place the application in	n condition for allowar	nce because:		
<ul><li>12.  Note the attached Information Disclosure Statement(s).</li><li>13.  Other:</li></ul>	(PTO/SB/08) Paper No(s)				
		/J.E. Angell/ Primary Examiner			

**Application No. 10/776,933** 

## **Continuation Sheet (PTO-303)**

Continuation of 3. NOTE: Currently, the independent claim, claim 91, is amended. Applicant argues that the newly entered claim limitation wherein the at least 8 nucleotides "being a contiguous portion" is fully supported in the specification as orginally filed. Applicant particularly points to the "paragraph bridging pages 12-13 of the specification as filed"; however, the Examiner was unable to locate any context that relates to the newly entered claim limitation in that paragraph. Furthermore, the only paragraph that contains the word "contiguous" is found on page 25. In the paragraph of page 25, nowhere is the claimed limitation of a subsequence of 8 contiguous nucleotides described as required by the claim. Since the alleged support for the newly entered claim limitation is not found in the specification as originally filed, and since all pending claims depend from the amended claim, claim 91, the proposed claim amendments raise the issues of further consideration and new matter.

Continuation of 11, does NOT place the application in condition for allowance because: the newly proposed claim amendments introduce new matter and therefore are not entered. See above NOTE.